This is in contrast to the studies by Cuyas et al.16 and Molenaar et al.,49 where, respectively, an increased sensitivity for metformin was identified in an engineered IDH1 mutant breast cancer cell line, and in an engineered IDH1 mutant colorectal cancer cell line compared to their wildtype parental cells. This evidence concerns the gene IDH1 and breast carcinoma.